Emmaus Life Sciences delays Q3 report to complete convertible note valuation
EMMA•Emmaus Life Sciences expects to file its delayed September 30, 2026, Form 10-Q within five calendar days of the deadline. It expects revenue to fall more than 40% and a net loss of about $0.06 per share, subject to a convertible-note valuation.
1. Filing delay and estimates
Emmaus Life Sciences said it needs additional time to value the conversion feature of outstanding convertible promissory notes and expects to file its delayed September 30, 2026, Form 10-Q within five calendar days of the prescribed deadline. Net revenue is expected to decline more than 40% following completion of the U.S. Endari out-license to NeoImmuneTech during the quarter. The company expects an operating loss of about $400,000, compared with operating income of about $700,000 a year earlier, and an estimated net loss of about $0.06 per share versus $0.03, subject to the final valuation.




